Mon Apr 24 CYPH [external] Online Investor: Stock buybacks - at CBS MarketWatch
Tue Apr 18 CYPH Cytoclonal Pharmaceutics Approves Repurchase of Common Stock - Business Wire
Mon Apr 17 CYPH Cytoclonal Pharmaceutics Raises $25 Million From Class D Warrant Redemption Results in Current Cash of $41 Million - Business Wire
Tue Apr 11 CYPH Cytoclonal Pharmaceutics Adds Michael N.G. James to Advisory Board - Business Wire
Mon Apr 10 CYPH Cytoclonal Announces Production System for Gaucher's Disease - Business Wire
Cytoclonal Could Benefit From Clinton-Blair Proposal On the Human Genome
DALLAS--(BW HealthWire)--March 16, 2000--Cytoclonal Pharmaceutics Inc. (NASDAQ: CYPH - news, CYPHZ - news) today indicated it could benefit from the proposal of President Clinton and Prime Minister Blair to make the information of the human genome available to the research community.
Cytoclonal's lead programs Oasis(TM) and Quantum Core Technology(TM) (QCT(TM)) make drugs against gene and protein targets from the human genome.
``Cytoclonal is addressing the next stage after the human genome, namely, making drugs against the genes using Oasis(TM) and against the proteins using QCT(TM),'' said Dr. Arthur P. Bollon, Chairman and Chief Executive Officer of Cytoclonal. ``The availability of the human genome target information gives us greater accessibility for developing these drugs.''
The Oasis(TM) platform technology is a library of optimized antisense reagents to regulate genes involved in diseases. The patented technology is being expanded to include reagents for all human genes. These reagents are potential therapeutic drugs and reagents to confirm function to genes from the human genome. Several antisense reagents are in development against cancer related genes including PKC.
Quantum Core Technology(TM) involves a novel drug design technology against protein targets from the human genome. Novel drugs using QCT(TM) are in development for cancer and the common cold. The QCT(TM) technology targets the mechanism of the protein for drugs that are small, cost effective, reduced toxicity, and reduced drug resistance. The QCT(TM) team includes world leaders under the direction of Dr. Dorit Arad and includes advisory board member Dr. John Pople who received the Nobel Prize in chemistry in 1998.
Cytoclonal Pharmaceutics is a biopharmaceutical company specializing in the development of therapeutic and diagnostic products for the treatment and prevention of cancer and infectious diseases. Based in Dallas, Texas, the Company's lead programs involve paclitaxel (active ingredient in TaxolŽ) production using fermentation and genetic engineering in agreements with Bristol-Myers Squibb, the treatment of Polycystic Kidney Disease using paclitaxel, Quantum Core Technology(TM), the Company's proprietary rational drug design targeting the human genome and OASIS(TM) optimized antisense library for regulating genes. Other programs involve the discovery of human genes through Retroselection(TM) with a focus on lung cancer, breast cancer treatment by peptide inhibition of estrogen receptors and the ``immortality enzyme'' telomerase. Additional information on Cytoclonal can be found on the Company's website at www.cytoclonal.com.
Market Capitalization $107.0M
Shares Outstanding 10.4M
Float 6.30M
